Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
50
Participants
Timeline
Start Date
October 31, 2003
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
Conditions
Adrenal Cortex Neoplasms
Interventions
DRUG
XR9576 (Tariquidar)
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00071058 - Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer | Biotech Hunter | Biotech Hunter